Last reviewed · How we verify
Comparator: Losartan
Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Comparator: Losartan |
|---|---|
| Also known as | MK0954, Losartan |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors in vascular smooth muscle and the adrenal gland. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone-mediated sodium and water retention, resulting in blood pressure reduction and improved renal protection.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
- Heart failure with reduced ejection fraction
- Post-myocardial infarction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
- Renal impairment
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka (PHASE1)
- ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED) (PHASE4)
- HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED) (PHASE3)
- Health Assessment Study (0954-946) (PHASE3)
- Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED) (PHASE4)
- A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) (PHASE3)
- Efficacy and Safety of Telmisartan Compared With Losartan (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Losartan CI brief — competitive landscape report
- Comparator: Losartan updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI